Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $305.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 0.99% year-over-year to $305.5 million; the TTM figure through Mar 2026 stood at $305.5 million (up 0.99% YoY), while the FY2025 annual figure was $277.1 million, down 29.82% from the prior year.
• Total Current Liabilities was $305.5 million for Q1 2026 at Acadia Pharmaceuticals, up from $277.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $394.9 million in Q4 2024 to a low of $116.6 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $255.0 million across 5 years, with a median of $277.1 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 102.38% in 2023, then declined 29.82% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $125.6 million in 2022, then soared by 102.38% to $254.3 million in 2023, then surged by 55.31% to $394.9 million in 2024, then slipped by 29.82% to $277.1 million in 2025, then gained by 10.25% to $305.5 million in 2026.
• The last three Total Current Liabilities figures came in at $305.5 million (Q1 2026), $277.1 million (Q4 2025), and $356.6 million (Q3 2025), per Business Quant data.